Hartalega

Figures are from Hartalega's annual audited financial statements (FY2022–FY2026), presented on a standardised basis by S&P Global Market Intelligence, and from the company's results announcements. Net income is profit attributable to owners of the company.

Income statement

The Q4 FY2023 results announcement reported a full-year net loss of RM218.0 million; the audited loss attributable to owners in the FY2023 annual report was RM235.1 million, which includes the RM347 million Bestari Jaya impairment.

Diluted EPS is equal to basic EPS in each year, as Hartalega has no material dilutive instruments outstanding.

Revenue compound annual growth from FY2022 to FY2026 was -27.9%, reflecting the unwinding of pandemic pricing. From the FY2024 trough to FY2026 the two-year revenue CAGR was +7.8%.

Commentary. The five-year record traces a complete boom-bust cycle. FY2022 captured the tail of the pandemic super-cycle, with ASPs that peaked well above USD60 per 1,000 pieces and a net margin of 41%; net profit would have been higher still without the one-off prosperity tax, which tipped Q4 FY2022 into the company's first-ever quarterly loss. FY2023 saw revenue collapse by 69% as distributor destocking met a wave of new capacity, while natural gas tariffs and Malaysia's new minimum wage lifted costs; the Bestari Jaya impairment pushed the year into a statutory loss. FY2024 marked the trough, with revenue of RM1.84 billion and net profit of just RM12.5 million as Bestari Jaya was wound down and NGC utilisation hovered near the mid-50s per cent.

FY2025 was a volume-led recovery: sales volume rose 40% to 26.5 billion pieces as US customers restocked ahead of higher tariffs on Chinese gloves, lifting revenue 41%. However, margins stayed thin because of adverse foreign-exchange movements and higher non-operating expenses. FY2026 inverted the pattern: revenue fell 17.4% because ringgit appreciation of more than 7% against the US dollar in calendar 2025, lower volume in the first half and Chinese price competition outside the US compressed ringgit ASPs, yet net profit rose 38% to RM103.0 million as automation, higher plant utilisation and tighter cost control reduced unit costs. Operating profit reported by the company rose 72.3% to RM91.7 million.

Quarterly trajectory

Q1 FY2026 included an RM11.3 million gain on disposal of Bestari Jaya assets; excluding it, core net profit was only about RM1.3 million. Q3 FY2026 core net profit was about RM44.1 million after excluding a RM16 million unrealised foreign-exchange loss and other one-offs. In Q1 FY2027 (April–June 2026) revenue rose 18% quarter-on-quarter on a 27% increase in ASPs, which more than offset a 7% fall in volume. ASPs rose in step with raw material costs that escalated because of the Middle East conflict. Operating profit reached RM80.0 million, pre-tax profit RM90.5 million and EBITDA about RM128 million, an EBITDA margin of roughly 21% versus 16% in Q4 FY2026.

Balance sheet

Commentary. Hartalega is effectively debt-free. Borrowings that funded the NGC build-out were repaid between FY2022 and FY2025, and total debt of RM9.4 million at end-FY2026 consists mainly of minor term loans and lease liabilities. Net cash fell from RM2.16 billion in FY2022 to RM0.94 billion in FY2025 because of large dividend payments (RM2.99 billion in FY2022, RM0.40 billion in FY2025), capital expenditure on NGC, the prosperity tax payment and two years of negative operating cash flow during the downturn. It rebuilt to RM1.16 billion at end-FY2026 and was about RM1.1 billion at 30 June 2026, equal to roughly 33 sen per share or about 30% of the market capitalisation. Construction-in-progress within PPE fell from about RM1.03 billion in FY2024 to RM339 million in FY2026 as NGC plants were completed and commissioned. Land holdings rose to about RM306 million, reflecting the Sepang, Banting and Kedah land bank held for future expansion. Goodwill of RM2.35 million appeared in FY2026 following a small acquisition.

Cash flow

Commentary. Operating cash flow was negative in FY2023 and FY2024 despite positive EBITDA, because the group paid RM442 million of tax in FY2023 (largely prosperity-tax and pandemic-era liabilities) and rebuilt inventories in FY2024 as volumes recovered. FY2026 operating cash flow of RM330.2 million was the strongest since FY2022, helped by a RM106.9 million release of working capital. Capital expenditure classified as purchases of property, plant and equipment fell to RM1.3 million in FY2026; total investing outflows were RM94.5 million, including other investing items. Capex is set to rise in FY2027 with the recommissioning of Plant 3. In Q1 FY2027 working capital absorbed cash as inventories rose to RM465 million, reflecting higher-cost raw material stocks.

Returns, liquidity and efficiency ratios

Commentary. Returns have fallen from extraordinary pandemic levels to well below the company's cost of capital. ROE of 2.3% in FY2026 is held down both by thin margins and by a large equity base that includes over RM1 billion of low-yielding cash and land held for expansion that has been deferred. Trailing twelve-month ROE to June 2026 improved to about 3.7% and ROIC to about 4.9% after the strong Q1 FY2027. Liquidity is exceptionally strong, with a current ratio above 6x. The cash conversion cycle lengthened sharply in FY2024 as inventories were rebuilt and customers took longer to pay; it has since normalised to about 83–88 days.

Management guidance

• Q2 FY2027 sales volume broadly flat quarter-on-quarter, with ASPs correcting faster than input costs, so margins normalise from Q1 FY2027's elevated level.

• Running-line utilisation of about 96%; Plant 3 restart from December 2026, with monthly output targeted at 2.4–2.5 billion pieces by end-2026.

• Capacity of about 30 billion pieces by end-2027, potentially 34–36 billion with Plants 3 and 4.

• Long-term glove demand growth of 7–9% a year.

• Continued investment in automation, efficiency and technology; no new greenfield expansion while oversupply persists.

Consensus expectations

Revenue (RM m): FY2026 actual: 2135; FY2027 broker forecast: 2650

Net profit (RM m): FY2026 actual: 103; FY2027 broker forecast: 148

The FY2027 figures are Berjaya Research's forecasts from February 2026; Q1 FY2027 net profit of RM70 million represented about 43–53% of various brokers' full-year forecasts, implying upside risk to FY2027 estimates even if margins normalise.

Bull case

1. Operating leverage on a lean cost base: FY2026 showed that cost optimisation can lift profit 38% on a 17% revenue decline; adding Plant 3 volume at about 96% running utilisation should improve fixed-cost absorption further.

2. US tariff moat: With 100% Section 301 tariffs on Chinese medical gloves in 2026 and North America at about half of revenue, Hartalega is structurally advantaged in its most profitable market.

3. Valuation support: The shares trade below tangible book value (0.9x) with net cash of about 33 sen per share, roughly 30% of the share price, limiting downside and allowing generous capital returns.

Bear case

1. Chinese overcapacity is unresolved: Intco's installed capacity rose from 87 billion to 103 billion pieces in 2025 and continues to grow, keeping industry utilisation below equilibrium and capping ASPs outside the US.

2. Q1 FY2027 margins were a one-off: Kenanga and TA Research expect ASPs to correct faster than input costs, with high-cost inventory weighing on margins in coming quarters.

3. Returns remain sub-par: Even with trailing-twelve-month ROE of about 3.7%, returns are far below the cost of equity, and a large idle land bank depresses capital efficiency.

Key catalysts and monitorables (next 12 months)

Q2 FY2027 results: Expected timing: ~10–11 November 2026; Why it matters: Magnitude of margin normalisation after Q1 FY2027's ASP spike

Plant 3 recommissioning: Expected timing: December 2026 onward; Why it matters: Volume growth and fixed-cost absorption

Q3 FY2027 results: Expected timing: February 2027; Why it matters: Run-rate profitability post-normalisation

NBR and natural gas prices: Expected timing: Ongoing; Why it matters: Direction of input costs and ASP pass-through

USD/MYR exchange rate: Expected timing: Ongoing; Why it matters: Ringgit strength reduces reported revenue

US trade policy toward Malaysia and China: Expected timing: Ongoing; Why it matters: Sustains or erodes the tariff advantage

Intco and Chinese capacity additions in Southeast Asia: Expected timing: Ongoing; Why it matters: Risk of tariff circumvention and renewed price war

Resolution of the RM101.36 million tax assessment: Expected timing: Uncertain; Why it matters: Potential one-off cash outflow

FY2027 results and dividend: Expected timing: May 2027; Why it matters: Capital return policy given about RM1.1 billion net cash

Analyst verdict

Hartalega has emerged from the deepest downturn in the glove industry's history as a leaner, debt-free operator with a still-dominant position in nitrile gloves, but it has not yet emerged as a business earning an adequate return on capital. The evidence of operational progress is real: by consolidating all production at NGC, automating heavily and running fewer, faster lines, management turned a 17% fall in FY2026 revenue into a 38% rise in net profit, and the company delivered RM70 million of net profit in Q1 FY2027 alone. The balance sheet, with about RM1.1 billion of net cash and virtually no debt, gives it the endurance that weaker rivals lack, and US tariffs of up to 100% on Chinese medical gloves protect its largest market.

The problem is that Hartalega's fortunes still hinge on variables it does not control. Standard nitrile examination gloves remain a commodity in which Chinese producers, led by Intco, are adding capacity faster than demand and appear willing to tolerate thin margins to gain share. Q1 FY2027's earnings spike was driven by a raw-material shock linked to the Middle East conflict that allowed sharp ASP increases, and both management and analysts expect those margins to normalise. Ringgit strength is a further, persistent drag on reported revenue.

At about 0.9x book value and with net cash covering roughly 30% of its market value, the shares already discount a great deal of pessimism, and the restart of Plant 3 offers measurable earnings leverage over the next 12–18 months. The stock is best viewed as a well-financed, operationally improving cyclical. On balance, a neutral stance with a positive bias toward capital returns is the most defensible view.

Your limit resets at 6:20 AM. Turn on notifications and Claude will notify you then.

Wait for the reset, or keep working now with usage credits, billed on top of your plan.

Get notified